Cygnus Technologies, part of Maravai LifeSciences, provides best-in-class analytical tools and solutions to help companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. As the biopharmaceutical industry’s partner in analytics for host cell proteins (HCP), other process-related impurities, and viral clearance, Cygnus’ off-the-shelf products and custom services ultimately improve bioprocess development for faster regulatory approval and better clinical outcomes.